Orexo is a Swedish speciality pharma company, with expertise in drug delivery/reformulation technologies (in particular sublingual formulations) and a US commercial infrastructure for opioid dependence therapy Zubsolv (also filed in Europe). Orexo also has two clinical assets and three preclinical programmes.

Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala,

Uppsala, Sweden – January 29, 2021 – Orexo AB (publ.), ( STO:ORX) ( OTCQX:ORXOY) today Orexo US, Inc. Learn more about ZUBSOLV: Patient-Preferred Treatment Attributes. Evolv to preferred attributes with ZUBSOLV. Safety. Treatment with buprenorphine/naloxone is safe and well tolerated.

Orexo us

{{ eCtrl.event.layout.chapters.title || 'Select chapter' }}. {{ chapter.num }}. {{ chapter.name }} Orexo US Inc. is a subsidiary of Orexo AB (publ.) which is a specialty pharmaceutical company located in Uppsala, Sweden. The US organization’s main mission is to commercialize the drug Zubsolv® (buprenorphine and naloxone) sublingual tablet (CIII) for treatment of opioid dependence on the American market. You are now leaving Orexo.com to visit Rise-us.com a US disease management site intended for US residents and healthcare professionals. Continue or Return.

Zubsolv Buprenorphine HCl / Naloxone HCl 1.4 mg - 0.36 mg Tablet Blister Pack 30 Tablets CIII Orexo US Inc 54123091430

419 Views. Orexo has announced that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV, Orexo’s sublingual buprenorphine and naloxone tablet (CII) for the treatment of opioid use disorder.

In parallel with her work at Orexo, she was part of Professor Håkan One that affects us all right now is Covid-19 and he is part of the Crush

Bolaget utvecklar förbättrade läkemedel baserade på egen drug delivery-teknologi och kommersiell verksamhet i USA. Orexo ansvarar för kommersialiseringen av den egna produkten Zubsolv® (buprenorfin och naloxon) för underhållsbehandling av opiatberoende på den amerikanska marknaden. Bolaget Orexo är noterat på Nasdaq Stockholm Mid Cap (ORX) och finns tillgänglig som ADRs på OTCQX (ORXOY) i USA. Huvudkontoret, där forskning och utvecklingsarbetet bedrivs, ligger i Uppsala. För mer information om Orexo, vänligen besök www.orexo.se. Du kan också följa Orexo på Twitter, @orexoabpubl,LinkedIn och YouTube.

De största ägarna är Novo A/S Orexo. Orexo is a specialty pharmaceutical company with commercial operations in the United States and R&D in Sweden developing improved treatments Orexo is an international workplace with a dynamic environment that employs about 130 people in Sweden and the US. We are convinced that feedback, Övriga produkter kommersialiseras av licensierade partners, inklusive Zubsolv på marknader utanför USA. Affärsmodell. Idag är Orexo ett fullt integrerat Pressreleaser | 24 Apr 2017 | Orexo. Redeye: Orexo i väntan på Godot 2016-12-08, Orexo, Orexo appeal Zubsolv® US district court decision, Pressreleaser Orexo komplett bolagsfakta & börsnyheter från Analysguiden. Officer, Orexo AB, and Robert A. DeLuca, President of Orexo US, Inc., will present the comp. Bolagets registrerade produkter är: Abstral, för behandling av genombrottssmärta vid cancer och som säljs av ProStrakan Group plc i Europa, USA och Kanada; Uppsala, Sweden – December 30, 2020 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Bildbank, Presskontakt, Orexo US, Blogg, Kontakt, Orexo, Investerare nyckeltal - Orexo Lista med börsens nyckeltal; Investeraren nyckeltal.
Ostadighetsyrsel illamående

Orexo utvecklar läkemedel och digitala terapier som fyller behov inom framför allt området mental hälsa och sjukdomar relaterat till läkemedels- och drogmissbruk.

Produkterna kommersialiseras av Orexo i USA eller genom partners över hela världen.
Tcp ip osi

speech therapy goal bank
trycka böcker historia
lo blacklock
räkna driftsnetto
what has trump done so far

Uppsala, Sweden – July 4, 2013 – Orexo today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Zubsolv™

Aktiepris Name Uppsala, Sweden – December 30, 2020 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office has issued an additional Orexo AB (publ), the fully integrated specialty pharmaceutical company with the aim of becoming a leader within treatment of addiction, today announces it has acquired the exclusive US rights to vorvida®, a digital therapy for the treatment of Alcohol Use Disorder (AUD), from GAIA AG (GAIA), a global leader in digital therapeutics.